PMID- 29496227 OWN - NLM STAT- MEDLINE DCOM- 20181221 LR - 20181221 IS - 1532-866X (Electronic) IS - 0049-0172 (Linking) VI - 48 IP - 2 DP - 2018 Oct TI - Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. PG - 168-175 LID - S0049-0172(17)30650-9 [pii] LID - 10.1016/j.semarthrit.2018.01.009 [doi] AB - INTRODUCTION: Hyaluronic acid (HA) is a commonly prescribed intra-articular (IA) therapy for knee osteoarthritis (OA). While a single series of IA-HA has been well studied, the efficacy and safety of repeated courses of IA-HA injection therapy in knee OA patients have not been evaluated as frequently. METHODS: A literature search was conducted using MEDLINE, EMBASE and PubMed databases. The primary outcome measure was knee pain reduction after each treatment course and/or last reported follow-up visit. Secondary outcomes were treatment-related adverse events (AEs) and serious adverse events (SAEs). RESULTS: A total of 17 articles (7 RCTs and 10 cohort studies) met the pre-defined inclusion criteria. Of the RCTs, six were double-blind with two trials including open label extension studies, and one was single-blind. Studies ranged from investigating a single reinjection cycle to four repeat injection cycles. Eleven studies evaluated one reinjection, five studies evaluated >/=2 repeated courses of IA-HA, and one study allowed either one or two repeated courses. All studies reported pain reduction from baseline in the IA-HA treatment group throughout the initial treatment cycle, and either sustained or further reduced pain throughout the repeated courses of treatment. The study with the longest follow-up repeated IA-HA injection every 6 months for 25 months. Pain decreased after the first course and continued to decrease until the end of the study, with an approximate 55% reduction in pain compared to baseline. Common AEs were joint swelling and arthralgia; there were no reported SAEs. All repeated courses were well tolerated, and the number of documented AEs and SAEs was similar to the primary injection regimens. CONCLUSION: Repeated courses of IA-HA injections are an effective and safe treatment for knee OA. Repeat courses were demonstrated to maintain or further improve pain reduction while introducing no increased safety risk. CI - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Altman, Roy AU - Altman R AD - Division of Rheumatology and Immunology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA. Electronic address: journals@royaltman.com. FAU - Hackel, Josh AU - Hackel J AD - Andrews Institute for Orthopaedics & Sports Medicine, FL. FAU - Niazi, Faizan AU - Niazi F AD - Ferring Pharmaceuticals Inc., Parsippany, NJ. FAU - Shaw, Peter AU - Shaw P AD - Ferring Pharmaceuticals Inc., Parsippany, NJ. FAU - Nicholls, Mathew AU - Nicholls M AD - Virginia Mason Orthopaedics and Sports Medicine, Seattle, WA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20180131 PL - United States TA - Semin Arthritis Rheum JT - Seminars in arthritis and rheumatism JID - 1306053 RN - 0 (Viscosupplements) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Humans MH - Hyaluronic Acid/adverse effects/*therapeutic use MH - Injections, Intra-Articular MH - Knee Joint MH - Osteoarthritis, Knee/*drug therapy MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Viscosupplements/adverse effects/*therapeutic use OTO - NOTNLM OT - Intra-articular hyaluronic acid (IA-HA) OT - Knee OT - Osteoarthritis (OA) EDAT- 2018/03/03 06:00 MHDA- 2018/12/24 06:00 CRDT- 2018/03/03 06:00 PHST- 2017/09/28 00:00 [received] PHST- 2018/01/11 00:00 [revised] PHST- 2018/01/16 00:00 [accepted] PHST- 2018/03/03 06:00 [pubmed] PHST- 2018/12/24 06:00 [medline] PHST- 2018/03/03 06:00 [entrez] AID - S0049-0172(17)30650-9 [pii] AID - 10.1016/j.semarthrit.2018.01.009 [doi] PST - ppublish SO - Semin Arthritis Rheum. 2018 Oct;48(2):168-175. doi: 10.1016/j.semarthrit.2018.01.009. Epub 2018 Jan 31.